吉西他滨联合培美曲塞治疗晚期非小细胞肺癌

目的观察吉西他滨联合培美曲塞方案治疗晚期非小细胞肺癌（NSCLC）的疗效及毒性。方法经组织学证实的NSCLC患者13例,给予吉西他滨联合培美曲塞方案化疗：吉西他滨（gem c itab ine）1 000 mg/m2,静脉注射,d1、d8;培美曲塞（pem etrexed）500 mg/m2,静脉注射,d1。培美曲塞用药前预防性应用维生素B12、叶酸及地塞米松。21-28天为1个周期。2周期后进行疗效评价。结果完全缓解（CR）0例,部分缓解（PR）2例,稳定（SD）5例,进展（PD）6例,有效率（RR）为15.4%,临床获益率（CBR）为53.8%。中位疾病进展时间（TTP）为4.4（2-6）月。主要毒性反应为骨髓抑制,表现为可逆性的白细胞减少及血小板减少。结论吉西他滨联合培美曲塞方案治疗晚期非小细胞肺癌是一种疗效可靠,毒性可以耐受的方案。

Clinical effects of gemcitabine combined with pemetrexed on patients with advanced non-small cell lung cancer

Objective To evaluate the efficacy and toxicity of gemcitabine plus pemetrexed in patients with advanced non-small cell lung cancer（NSCLC）.Methods Thirteen patients with NSCLC diagnosed by pathology or cytology were enrolled into the study.The patients received gemcitabine plus pemetrexed： gemcitabine 1 000 mg/m2,iv,d1,d8;pemetrexed 500 mg/m2,iv,d1.Each patient used folate,vitamin B12 and dexamethasone prophylacticly before pemetrexed.One cycle was 21-28 days.The efficacy and toxicity were evaluated every two cycles.Results There was no patient observed in complete remission（CR）,2 cases in partial remission（PR）,5 in stable disease（SD）,6 in progressive disease（PD）.The response rate（RR） was 15.4%,clinical benefit rate（CBR） was 53.8%.The main side effects were reversible leucopenia and thrombocytopenia.Conclusion The combination of gemcitabine and pemetrexed is effective,safe and tolerable in the treatment of advanced NSCLC.